Thermo Fisher Scientific (TMO) return on equity (ROE)

Return on equity · fiscal 2025
12.6%

Thermo Fisher Scientific (TMO) earned a return on equity of 12.6% in fiscal 2025 (the year ended December 31, 2025). That is 0.2 percentage points lower than the 12.8% of fiscal 2024. Figures as of 18 Nov 2026, 00:25 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
12.6%
Change on fiscal 2024
−0.2 pts
Highest on record
18.9%fiscal 2021
Lowest on record
5.2%fiscal 2007
Fiscal years on record
142007–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Thermo Fisher Scientific return on equity (ROE), in more detail

Across the 14 fiscal years on record (2007–2025), the highest was 18.9% in fiscal 2021 and the lowest 5.2% in fiscal 2007. The fiscal 2025 figure is higher than in 62% of the 13 earlier fiscal years on record, whose median is 8.8%.

History · 14 fiscal years

Return on equity by fiscal year

Thermo Fisher Scientific return on equity (ROE), year by year

Thermo Fisher Scientific (TMO) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202512.6% 0.2 pts down
202412.8% 0.1 pts down
202312.8% 3.0 pts down
202215.8% 3.1 pts down
202118.9% 0.5 pts up
202018.5% 6.0 pts up
201912.5%—
20137.6% 0.1 pts down
20127.6% 1.2 pts down
20118.8% 2.1 pts up
20106.7% 1.2 pts up
20095.5% 1.1 pts down
20086.6% 1.4 pts up
20075.2%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Thermo Fisher Scientific and comparable companies
CompanyReturn on equityFiscal year
UnitedHealth Group UNH12.8%2025
Novartis NVS30.3%2025
AstraZeneca AZN21.0%2025
Thermo Fisher Scientific TMO12.6%2025
Amgen AMGN89.1%2025
Gilead Sciences GILD37.5%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on TMO

Thermo Fisher Scientific, figure by figure

Thermo Fisher Scientific (TMO) overview: price, valuation and scorecardAll health care companies by market value

Thermo Fisher Scientific return on equity (ROE): questions and answers

What is Thermo Fisher Scientific's return on equity?

Thermo Fisher Scientific (TMO) earned a return on equity of 12.6% in fiscal 2025 (the year ended December 31, 2025). That is 0.2 percentage points lower than the 12.8% of fiscal 2024.

Is Thermo Fisher Scientific's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 62% of the 13 earlier fiscal years on record, whose median is 8.8%.

What are the highest and lowest return on equity figures on record for Thermo Fisher Scientific?

Across the 14 fiscal years on record (2007–2025), the highest was 18.9% in fiscal 2021 and the lowest 5.2% in fiscal 2007.

How is Thermo Fisher Scientific's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Thermo Fisher Scientific (TMO) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/TMO/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.